Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis' CAR-T CTL019 Back On The Blockbuster Hit List

Jun 01 2017

• By Jessica Merrill

Leukemia cell (blast cell)

Related Content

A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Nov 26 2012

ASCO CAR-T Highlights: Exploring New Frontiers For The Field

Jun 01 2017

BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite

Mar 30 2017

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

Jul 19 2016

Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big

Aug 31 2016

Related Companies

Novartis AG

Kite Pharma, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

Pfizer Inc.

AstraZeneca PLC

Additional Topics

Business Strategies Pricing Strategies ImmunoOncology Commercial Cancer BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window